BioNTech Slips Into Quarterly Loss As Q2 Revenue Evaporates, Cuts R&D Spending For FY23
Portfolio Pulse from Vandana Singh
BioNTech SE (BNTX) reported Q2 revenues of €167.7 million, a significant drop from €3.2 billion a year ago. The company's gross profit share was reduced due to write-offs by collaboration partner Pfizer Inc (PFE). BioNTech also reported an EPS loss of €(0.79) compared to an income of €6.45 a year ago. The company reiterated its Covid-19 vaccine revenue guidance at approximately €5 billion and reduced its R&D expenses and Capex guidance.
August 07, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioNTech reported a significant drop in Q2 revenues and an EPS loss, which could negatively impact its stock price.
BioNTech's Q2 revenues and EPS fell significantly, which could lead to a decrease in its stock price as investors may see this as a sign of poor financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Pfizer's write-offs significantly reduced BioNTech's gross profit share, which could have a negative impact on Pfizer's stock price.
Pfizer's write-offs reduced BioNTech's gross profit share, which could negatively impact Pfizer's stock price as it shows a potential loss on their investment in BioNTech.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50